Previous Close | 37.71 |
Open | 37.60 |
Bid | 37.72 x 200000 |
Ask | 38.01 x 200000 |
Day's Range | 37.51 - 37.72 |
52 Week Range | 29.80 - 44.40 |
Volume | |
Avg. Volume | 26 |
Market Cap | 374.45B |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | May 02, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Besides Wall Street's top -and-bottom-line estimates for Baxter (BAX), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Baxter's (BAX) first-quarter results are likely to reflect growth in elective surgical procedures and a more stable supply chain.
ResMed (RMD) delivered earnings and revenue surprises of 10.94% and 1.90%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?